Meta Pixel

News and Announcements

HealthTech announces acceptance into the government-backed MDPP

  • Published April 29, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

“MDPP has been incredibly valuable to Peak Medical, building and validating an MVP, giving access to Peak Medical to work with world class researchers and engineers. It is a rigorous expert panel process to get into the program, with due diligence done on Peak Medical by the government and university supported program”. Hayley Saddington.

MTPConnect has launched a new program with industry partners this year supporting early clinical development of medical devices. The Clinical Translation and Commercialisation – Medtech (CTCM) program is a $19.75 million initiative funded by the Federal Government’s Medical Research Future Fund and will offer financial assistance, educational support and infrastructure access to Australian small to medium-sized enterprises (SMEs). The Medical Device Partnering Program (led by Flinders University) is proud to be announced as a partner on the program.  The other partners are the Medical Technology Association of Australia, Cicada Innovations, the BridgeTech Program and Therapeutic Innovation Australia. This is an exciting and advantageous ecosystem for Peak Medical to be supported by.

MDPP Director Professor Karen Reynolds said: “MDPP has a 13-year track record of supporting medical device ventures across the innovation life cycle, from ideation to product development to commercialisation. We’re delighted to now join MTPConnect and other partners to deliver the new CTCM program, leveraging our capabilities and extensive networks to assist Australian SMEs achieve key clinical milestones and accelerate the adoption and commercialisation of new devices.”

Register Interest

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now